tetano
Editor, Senior Moderator
Paediatr Drugs
. 2022 Apr 16.
doi: 10.1007/s40272-022-00500-7. Online ahead of print.
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study
Carlos K H Wong[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Marshall C H Low[SUP] #[/SUP][SUP] 4 [/SUP], Ashley C Y Kwok[SUP] #[/SUP][SUP] 4 [/SUP], Angel Y C Lui[SUP] 4 [/SUP], Kristy T K Lau[SUP] 4 [/SUP], Ivan C H Au[SUP] 4 [/SUP], Xi Xiong[SUP] 4 [/SUP], Matthew S H Chung[SUP] 4 [/SUP], Mike Y W Kwan[SUP] 5 [/SUP], Eric H Y Lau[SUP] 6 7 [/SUP], Benjamin J Cowling[SUP] 6 7 [/SUP]
Affiliations
Abstract
Objectives: There was initially insufficient understanding regarding suitable pharmacological treatment for pediatric Coronavirus Disease 2019 (COVID-19) patients. Lopinavir-ritonavir (LPV/r) was originally used for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection. It was also used in patients with severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) with positive results. Nonetheless, results from recent randomized controlled trials and observational studies on COVID-19 patients were unfavorable. We sought to evaluate the clinical outcomes associated with early treatment with LPV/r for pediatric COVID-19 patients.
Study design: A total of 933 COVID-19 patients aged ≤ 18 years were admitted between 21 January 2020 and 31 January 2021 in Hong Kong. Exposure was receiving LPV/r within the first two days of admission. Time to clinical improvement, hospital discharge, seroconversion and hyperinflammatory syndrome, cumulative costs, and hospital length of stay were assessed. Multivariable Cox proportional hazard and linear models were performed to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of time-to-event and continuous outcomes, respectively.
Results: LPV/r users were associated with longer time to clinical improvement (HR 0.51, 95% CI 0.38-0.70; p < 0.001), hospital discharge (HR 0.51, 95% CI 0.38-0.70; p < 0.001) and seroconversion (HR 0.59, 95% CI 0.43-0.80; p < 0.001) when compared with controls. LPV/r users were also associated with prolonged hospital length of stay (6.99 days, 95% CI 6.23-7.76; p < 0.001) and higher costs at 30 days (US$11,709 vs US$8270; p < 0.001) as opposed to controls.
Conclusion: Early treatment with LPV/r for pediatric COVID-19 patients was associated with longer time to clinical improvement. Our study advocates the recommendation against LPV/r use for pediatric patients across age groups.
. 2022 Apr 16.
doi: 10.1007/s40272-022-00500-7. Online ahead of print.
Slower Recovery with Early Lopinavir/Ritonavir use in Pediatric COVID-19 Patients: A Retrospective Observational Study
Carlos K H Wong[SUP] #[/SUP][SUP] 1 2 3 [/SUP], Marshall C H Low[SUP] #[/SUP][SUP] 4 [/SUP], Ashley C Y Kwok[SUP] #[/SUP][SUP] 4 [/SUP], Angel Y C Lui[SUP] 4 [/SUP], Kristy T K Lau[SUP] 4 [/SUP], Ivan C H Au[SUP] 4 [/SUP], Xi Xiong[SUP] 4 [/SUP], Matthew S H Chung[SUP] 4 [/SUP], Mike Y W Kwan[SUP] 5 [/SUP], Eric H Y Lau[SUP] 6 7 [/SUP], Benjamin J Cowling[SUP] 6 7 [/SUP]
Affiliations
- PMID: 35428969
- DOI: 10.1007/s40272-022-00500-7
Abstract
Objectives: There was initially insufficient understanding regarding suitable pharmacological treatment for pediatric Coronavirus Disease 2019 (COVID-19) patients. Lopinavir-ritonavir (LPV/r) was originally used for the treatment of Human Immunodeficiency Virus-1 (HIV-1) infection. It was also used in patients with severe acute respiratory syndrome (SARS) and Middle East Respiratory Syndrome (MERS) with positive results. Nonetheless, results from recent randomized controlled trials and observational studies on COVID-19 patients were unfavorable. We sought to evaluate the clinical outcomes associated with early treatment with LPV/r for pediatric COVID-19 patients.
Study design: A total of 933 COVID-19 patients aged ≤ 18 years were admitted between 21 January 2020 and 31 January 2021 in Hong Kong. Exposure was receiving LPV/r within the first two days of admission. Time to clinical improvement, hospital discharge, seroconversion and hyperinflammatory syndrome, cumulative costs, and hospital length of stay were assessed. Multivariable Cox proportional hazard and linear models were performed to estimate hazard ratios (HR) and their 95% confidence intervals (CI) of time-to-event and continuous outcomes, respectively.
Results: LPV/r users were associated with longer time to clinical improvement (HR 0.51, 95% CI 0.38-0.70; p < 0.001), hospital discharge (HR 0.51, 95% CI 0.38-0.70; p < 0.001) and seroconversion (HR 0.59, 95% CI 0.43-0.80; p < 0.001) when compared with controls. LPV/r users were also associated with prolonged hospital length of stay (6.99 days, 95% CI 6.23-7.76; p < 0.001) and higher costs at 30 days (US$11,709 vs US$8270; p < 0.001) as opposed to controls.
Conclusion: Early treatment with LPV/r for pediatric COVID-19 patients was associated with longer time to clinical improvement. Our study advocates the recommendation against LPV/r use for pediatric patients across age groups.